OncoCyte Corporation (LON:0KCC)

Market Cap	73.92M
Revenue (ttm)	1.50M
Net Income (ttm)	-48.67M
Shares Out	n/a
EPS (ttm)	-3.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	361
Open	3.080
Previous Close	n/a
Day's Range	3.080 - 3.080
52-Week Range	0.208 - 4.226
Beta	1.01
RSI	62.28
Earnings Date	May 9, 2025

About OncoCyte

OncoCyte Corporation, a precision diagnostics company in the United States and internationally. It develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. The company is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. It also offers VitaGraft Kidney, a blood-based transplant monitoring test that quant...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2009
• Employees: 49
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0KCC

Financial Performance

In 2024, OncoCyte's revenue was $1.88 million, an increase of 25.15% compared to the previous year's $1.50 million. Losses were -$60.93 million, 112.1% more than in 2023.

Financial numbers in USD